EGFR and non-small cell lung carcinoma: Regardless of the underlying mutations, amivantamab has proven efficacy in EGFR mutation-positive NSCLC (deletions within exon 19, L858R, L858R_T790M, L858R_T790M_C797S, exon 20 insertions).